Understanding the new therapeutic options for mesothelioma
Mené en Italie sur 161 patients atteints d'un mésothéliome pleural malin, cet essai de phase II évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du ramucirumab à la gemcitabine en traitement de deuxième ligne (durée médiane de suivi : 21,9 mois)
Since the US Food and Drug Administration (FDA) approved pemetrexed plus cisplatinfor first-line treatment of mesothelioma in 2004, there has been a dearth of additional treatment options for this disease. Despitesubstantial effort, no other phase 3 study achieved a positive outcome for another12 years, until the MAPS trial showed that the addition of bevacizumab to pemetrexedplus platinum improved progression-free and overall survival. Although it is not approved by regulatory agencies, bevacizumab is endorsed in treatmentguidelines for patients with no contraindications to its use, with variable uptake depending on the geographical region. No drugs have been approvedfor previously treated patients, but pemetrexed retreatment, gemcitabine, or vinorelbineare widely used, based on findings from single-group phase 2 trials and retrospectivesingle-centre series.
The Lancet Oncology 2021